Clinical trial · Interventional
Effect of Omega-3 Supplementation as Add on Therapy on Metabolic Syndrome in Women With Polycystic Ovary Syndrome.
Effect of Omega-3 Supplementation as Add on Therapy on Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Randomized Double-Blind, Placebo-Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn if Omega-3 works to treat Polycystic ovary syndrome in women. It will also learn about the safety of drug Omega-3. The main questions it aims to answer are: Does Omega-3 lower the number of times participant to treat metabolic syndrome What medical problems do participants have when taking drug Omega-3.Researchers will compare drug Omega-3 to a placebo (a look-alike substance that contains no drug) to see if drug Omega-3 used to treat PCOS. Participants will: Take Omega-3 or a placebo every day for 3 months Visit the clinic once every 6 weeks for checkups and tests Keep a diary of their symptoms and menstrual history.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| PCOS (Polycystic Ovary Syndrome) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Omega 3 fatty acids | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Omega-3
- description
- Participants received Omega-3 1gm tablet orally twice daily for 12 weeks.
- interventionNames
- Drug: Omega 3 fatty acids
- Drug: Omega -3 fatty acids
- type
- PLACEBO_COMPARATOR
- label
- placebo
- description
- Participants received Omega-3 1gm placebo matching Omega-3 tablet orally twice daily for 12 weeks
- interventionNames
- Drug: Omega 3 fatty acids
- Drug: Omega -3 fatty acids
Primary outcomes (1)
- measure
- Effect of Omega-3 Supplementation as Add on Therapy on Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 36 Years
Show eligibility criteria text
Inclusion Criteria:• Rotterdam criteria for PCOS (Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) 2004). * Age above 18 years up to 35 years * Newly diagnosed case of PCOS. Exclusion Criteria:• Pregnancy and lactating mother. * History of diabetes mellitus (except those meeting metabolic syndrome criteria) * Any chronic illness (e.g. liver disease, kidney disease, cardiovascular disease) * Any acute or chronic infective or inflammatory disease. * Patients receiving Omega-3 supplementation within the last three months. * Exclusion of PCOS mimicking disease include hyperprolactinemia, adrenal hyperandrogenism, ovarian hyperandrogenism, cushing's syndrome, acromegaly etc. * Known allergy to fish oil or Omega-3 supplements.
References
Publications (0)
Data not yet available